AC Immune AGM 2026: CEO Pfeifer Retires; Capital Band Proposed
AC Immune SA announced its Annual General Meeting (AGM) for June 11, 2026, where shareholders will vote on key proposals including the approval of 2025 financial statements and changes to the Articles of Association. Dr. Andrea Pfeifer will retire as CEO after 23 years, with Martin Zügel, Chair of the Board, appointed Interim CEO. The company also proposes to introduce a capital band and increase conditional share capital for employee benefit plans. Additionally, AC Immune reported positive clinical progress for its pipeline, including interim results for ACI-7104 in Parkinson's disease and advancement of its NLRP3 inflammasome inhibitor into Phase 1. A strategic review in 2025 resulted in a 30% workforce reduction and extended the cash runway into Q4 2027.
Key Highlights
- AGM 2026 scheduled for June 11, 2026, to approve 2025 financials and corporate actions.
- CEO Dr. Andrea Pfeifer to retire after 23 years; Martin Zügel appointed Interim CEO.
- Proposed capital band from CHF 2,202,018.50 to CHF 2,862,500.00 until June 11, 2031.
- Conditional share capital for employee plans to increase from CHF 86,683.80 to CHF 150,000.00.
- ACI-7104 (PD) Phase 2 VacSYn trial showed positive immunogenicity, safety, and biomarker trends.
- ACI-24 (AD) Phase 1b/2 ABATE trial progressing well; 12 months treatment completed in first 3 AD cohorts.
- NLRP3 inflammasome inhibitor (ACI-19764) advanced to Phase 1; SAD/MAD results expected H2 2026.
- Strategic review in 2025 led to 30% workforce reduction and cash runway extension into Q4 2027.
Price Impact
More from ACIU